Business Context and Reporting Period
Company: MYOMO, INC. (NYSE American: MYO)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2024
Business Overview: Myomo is a wearable medical robotics company developing myoelectric orthotics (MyoPro) for patients with neuromuscular disorders. The company primarily sells directly to patients and bills insurance providers (Direct Billing), with a significant portion of revenue derived from Medicare Part B beneficiaries following a CMS reclassification in early 2024.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $9.21 million | $5.08 million | $20.48 million | $14.48 million |
| Gross Profit | $6.95 million | $3.49 million | $14.57 million | $10.08 million |
| Gross Margin | 75.4% | 68.7% | 71.1% | 69.6% |
| Net Loss | $(0.97) million | $(2.03) million | $(5.92) million | $(5.69) million |
| Operating Cash Flow | N/A | N/A | $(6.66) million | $(3.82) million |
| Cash & Equivalents | $6.62 million (as of Sept 30, 2024) | |||
| Working Capital | $7.71 million (as of Sept 30, 2024) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 81% quarter-over-quarter (Q3 2024 vs. Q3 2023) and 41% year-to-date. This growth was driven by higher unit volumes, specifically deliveries to Medicare Part B patients, and higher average selling prices following new CMS fee determinations effective April 1, 2024.
- Margin Expansion: Gross margin improved to 75.4% in Q3 2024 from 68.7% in the prior year period, attributed to higher selling prices and fixed cost absorption, partially offset by increased manufacturing overhead.
- Operating Expenses: Total operating expenses rose 43% in Q3 2024 compared to Q3 2023. Increases were seen across all categories: R&D (+74%), Selling/Clinical/Marketing (+42%), and G&A (+35%), primarily due to headcount additions to support clinical capacity and reimbursement functions.
- Inventory Build: Inventory levels increased significantly to $3.38 million (up from $1.80 million at year-end 2023) to support anticipated volume growth.
Guidance, Outlook, and Risks
- Cash Flow Breakeven: Management believes it can achieve operating cash flow breakeven on a quarterly basis in the fourth quarter of 2024, contingent on supply chain stability, successful reimbursement collection, and no increase in days sales outstanding.
- Liquidity: The company holds approximately $6.6 million in cash and cash equivalents. It secured a $4.0 million revolving line of credit with Silicon Valley Bank in July 2024 (undrawn as of filing), with approximately $0.9 million available. Management believes current resources are sufficient for operations for the next 12 months.
- Key Risks:
- Reimbursement Concentration: Revenue is heavily concentrated with a few payers. CMS represented 55% of total product revenue in Q3 2024. Adverse changes in reimbursement policies or claim denials (notably from a large commercial insurer) pose significant risks.
- Supply Chain: The company relies on a single third-party manufacturer (Cogmedix) for key subassemblies and limited suppliers for components.
- Regulatory & Compliance: Risks include FDA regulatory actions, potential reclassification of devices, and compliance with healthcare fraud and abuse laws.
- Going Concern: While management believes substantial doubt regarding going concern is alleviated, the company has a history of operating losses and an accumulated deficit of $102.9 million.
Investor Verification Checklist
- CMS Reimbursement Stability: Verify the sustainability of the new CMS fee structure and the rate of claim approvals/denials for Medicare Part B and Medicare Advantage plans.
- Commercial Payer Denials: Monitor the status of appeals and payment collection from the large commercial insurer noted for post-service denials.
- Supply Chain Capacity: Confirm that the contract manufacturer (Cogmedix) can meet volume requirements without disruption as the company scales.
- Cash Burn Rate: Track the trajectory of operating cash flow to validate the Q4 2024 breakeven target.
- Inventory Turnover: Assess the risk of inventory obsolescence given the significant build-up in finished goods and parts.